Ascentage Pharma Group International (NASDAQ:AAPG) Receives “Buy” Rating from BTIG Research

BTIG Research reiterated their buy rating on shares of Ascentage Pharma Group International (NASDAQ:AAPG) in a research note published on Monday morning,Benzinga reports. BTIG Research currently has a $48.00 price objective on the stock.

Several other research analysts have also recently commented on the stock. China Intl Cap upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. Deutsche Bank Aktiengesellschaft began coverage on Ascentage Pharma Group International in a research note on Friday, April 24th. They issued a “buy” rating and a $40.00 price target on the stock. B. Riley Financial began coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat.com, Ascentage Pharma Group International presently has a consensus rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Price Performance

Shares of NASDAQ AAPG opened at $17.34 on Monday. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. Ascentage Pharma Group International has a 12-month low of $16.92 and a 12-month high of $48.45. The business’s fifty day simple moving average is $21.90 and its 200-day simple moving average is $24.59.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The business had revenue of $24.72 million for the quarter. As a group, equities research analysts expect that Ascentage Pharma Group International will post -0.96 EPS for the current year.

Institutional Trading of Ascentage Pharma Group International

Hedge funds and other institutional investors have recently bought and sold shares of the business. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the second quarter worth about $391,000. UBS Group AG grew its holdings in shares of Ascentage Pharma Group International by 149.4% during the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the last quarter. XY Capital Ltd grew its holdings in shares of Ascentage Pharma Group International by 224.2% during the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the last quarter. Finally, Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the third quarter worth about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.